### Bleomycin

**Indication:** Hodgkin lymphoma  

**INN:** Bleomycin

**Medicine type:** Chemical agent

**List type:** Complementary

**Formulations:** Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)

**EML status history:**
- First added in 1979 (TRS 641)
- Changed in 2015 (TRS 994)

**Sex:** All

**Age:** Also recommended for children

**Therapeutic alternatives:** The recommendation is for this specific medicine

**Patent information:** Patents have expired in most jurisdictions  
Read more about patents.

**Tags:** Cancer

**Wikipedia:** Bleomycin

**DrugBank:** Bleomycin

### Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for bleomycin on the complementary list of the EML and EMLc for use in treatment protocols for Hodgkin lymphoma was specifically endorsed. The relevant extracts from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for Hodgkin lymphoma in adults and in paediatrics are attached.